Close Menu

NEW YORK (GenomeWeb) – Dutch molecular diagnostics firm SkylineDx today announced it has received CE-IVD certification for its MMprofiler.

The test determines prognosis risk for multiple myeloma patients based on the SKY92 gene signature and is used to stratify patients into standard and high-risk groups. The firm said in a statement that the gene signature outperforms current standard risk indicators for myeloma, such as serum albumen levels and fluorescent in situ hybridization.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.